Overview
- 8 public-safe observations are available for this inspection.
- 4 structured CFR citations are represented.
- 3 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
7 Apr 2015
21 CFR 211.100(b)
SOPs not followed / documented
Cited by Debra I Love, Eileen A Liu, Narong Chamkasem
7 Apr 2015
21 CFR 211.111
Establishment of time limitations
Cited by Debra I Love, Eileen A Liu, Narong Chamkasem
7 Apr 2015
21 CFR 211.113(b)
Procedures for sterile drug products
Cited by Debra I Love, Eileen A Liu, Narong Chamkasem
7 Apr 2015
21 CFR 211.192
Investigations of discrepancies, failures
Cited by Debra I Love, Eileen A Liu, Narong Chamkasem
7 Apr 2015
21 CFR 211.100(b)
SOPs not followed / documented
Cited by Debra I Love, Eileen A Liu, Narong Chamkasem
Inspected site
IPIntas Pharmaceuticals LimitedAhmedabad, India
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.100(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.111 | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.113(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 2x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 8 observations
The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere